GlassScriptPhysician profile
Chaka Chipawe
NPI 1104378264
$9,295.18
in general payments reported to CMS, 2019-2025
37 companies · $1,548 in 2025
The $1,548 reported for 2025 was more than what 91% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,726 · 2022: $1,537 · 2023: $1,831 · 2024: $1,653 · 2025: $1,548.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,988 · Education: $44.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,988.02 |
| Education | $44.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,159.81 | 2021-2025 | |
| Indivior INC. | $918.87 | 2021-2025 | Sublocade |
| Novo Nordisk INC | $881.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Uswm, LLC | $659.93 | 2021-2024 | Lucemyra, Zimhi |
| Astrazeneca Pharmaceuticals LP | $654.01 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $597.00 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Braeburn INC. | $494.35 | 2023-2025 | Brixadi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $493.50 | 2021-2025 | Xifaxan |
| Vanda Pharmaceuticals INC. | $446.68 | 2022-2025 | Fanapt |
| Lilly USA, LLC | $387.61 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $343.66 | 2021-2025 | |
| Alkermes, INC. | $332.09 | 2021-2025 | Vivitrol, Vivitrol |
| Axsome Therapeutics, INC. | $274.86 | 2023-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.80 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $200.87 | 2021-2023 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chaka Chipawe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.